Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 202-849-4 | CAS number: 100-41-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://echa.europa.eu./o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Neurotoxicity
Administrative data
Description of key information
The potential neurotoxicity of ethylbenzene has been thoroughly assessed in studies conducted in adult and developing animals. No adverse effects on neurodevelopment were observed in F1 parental or F2 offspring were observed.
Key value for chemical safety assessment
Additional information
The potential neurotoxicity of ethylbenzene has been thoroughly assessed in studies conducted in adult and developing animals.
In the section for repeated dose toxicity, studies specifically related to ototoxicity are described in detail. Furthermore, a 90-day oral gavage study on male and female rats specifically designed to detect neurotoxic effects (according to the EPA OPPTS 877.6200 guideline, similar to OECD 424) has already briefly been mentioned in this section (Li et al., 2010). In this study young adult animals received gavage doses twice daily at 0, 25, 125 and 250 mg/kg per dose (total daily dosages of 0, 50, 250 and 500 mg/kg bw/d) and a post-exposure recovery group was added to the control and high dose animals. Apart from general and detailed clinical observations, parameters specifically related to neurotoxicity included ophthalmology, neurobehavioural assessments (functional observational battery – FOB, motor activity) and a detailed histopathology of the eye, brain, spinal cord, hindlimb peripheral nerves, and muscle. No adverse findings indicative for neurotoxicity were observed up to the highest dose of 500 mg/kg bw/d.
The negative findings in this study specifically designed for neurotoxicity testing are corroborated by the results of standard repeated dose studies: no adverse effects were observed in brain, spinal cord, and sciatic nerve in the 2-year bioassay in rats and mice by inhalation up to 750 ppm (NTP, 1999), in the 13-week inhalation study in rats and mice up to 1000 ppm (NTP, 1992), or in the 13-week oral gavage study in rats at doses up to 750 mg/kg bw/d including organs such as liver, kideneys, adrenals, testes, epididymes, ovaries, uterus, spleen, brain, heart, thymus,
ophthalmology, FOB, and motor activity (Mellert et al., 2007).
In a developmental neurotoxicity study (DNT) possible neurotoxic effects on the developing organism were investigated (WIL Research Laboratories Inc., 2005; Faber et al., 2007. F1 females and F2 pups (male and female) from the 2-generation study (Faber et al., 2006) were used. The F1 animals were treated by gavage from lactation days 1-4 at dose levels up to 342 mg/kg bw/d and subsequently by direct inhalation at 0, 25, 100, and 500 ppm. F2 animals were indirectly exposed via their mothers in utero and during lactation. Parameters investigated corresponded to those of OECD guideline 426.
In F1 animals: FOB.
In F2 animals: developmental landmarks, neurobehavioral evaluations (with FOB, locomotor activity, acoustic startle response, learning and memory in the water maze), and detailed investigations of the brain (weight, neurohistopathology, morphometry).
No adverse effects on neurodevelopment were observed in F1 parental or F2 offspring were observed.
The following information is taken into account for any hazard/risk assessment:
The potential neurotoxicity of ethylbenzene has been thoroughly assessed in studies conducted in adult and developing animals. No adverse effects on neurodevelopment were observed in F1 parental and F2 offspring were observed.
Justification for classification or non-classification
Based on the absence of behavioral or morphological changes indicative of specific, persistant, or progressive action on the nervous system in standard neurotoxicity studies of adult and developing animals, no classification of ethylbenzene for nervous system effects is warranted. (See repeated exposure toxicity section for recommended classification for auditory effects).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)